<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03757078</url>
  </required_header>
  <id_info>
    <org_study_id>20364</org_study_id>
    <nct_id>NCT03757078</nct_id>
  </id_info>
  <brief_title>Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)</brief_title>
  <official_title>Prospective Multicenter Non-interventional Study of Fluocortolone + Lidocaine Formulation in Patients With Acute Hemorrhoids to Evaluate Changes in Symptoms Severity During the Course of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study researcher want to learn more about the changes of biggest twisted and bulging
      veins in the rectal area (hemorrhoids) and changes of symptoms during a treatment period with
      the cream Relief Pro and suppositories Relief Pro. The study will also collect information on
      the treatment satisfaction of patients and their physicians with the prescribed treatment by
      using questionnaires. There will be 3 visits at the physician's clinic for this study: one
      initial visit and 2 follow-up visits over a period of 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Actual">October 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sodergren hemorrhoid symptom severity score by Sodergern scoring system</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Standardized answer options are given (4 and 5 Likert boxes) and each question gets a score from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the biggest hemorrhoid pile in size</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Size of the biggest hemorrhoid pile measured during routine examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator overall satisfaction with Relief Pro treatment by 5-point Likert scale</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Likert scale: 1 (Very satisfied), 2 (Satisfied), 3 (Neither satisfied nor dissatisfied), 4 (Dissatisfied) and 5 (Very dissatisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's adherence to recommendations of the Investigator by PRO</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>PRO: Patient Reported Outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient overall satisfaction with Relief Pro treatment by 5-point Likert scale</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Likert scale: 1 (Very satisfied), 2 (Satisfied), 3 (Neither satisfied nor dissatisfied), 4 (Dissatisfied) and 5 (Very dissatisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient preferences on dosage form by PRO</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Cream or Rectal suppository (not applicable for patients who received only one form)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Date of start and end using Relief Pro</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Assess drug utilization of Relief Pro</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily frequency of Relief Pro use, captured based on patient verbal response</measure>
    <time_frame>Up to 14 days (within period of use)</time_frame>
    <description>Assess drug utilization of Relief Pro</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of pain symptom (VAS)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Pain was measured on a Visual Analogue Scale (VAS) from 0 (No Pain) to 10 (Maximal Pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of bleeding symptom (4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Bleeding was measured on a 4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of itching symptom (4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Itching was measured on a 4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of swelling symptom (4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Swelling was measured on a 4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of discharge (4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Discharge was measured on a 4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the severity of discomfort (4-point Likert scale)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Discomfort were measured on a 4-point Likert scale consisting of: 1 (None), 2 (Minimal), 3 (Moderate) and 4 (Significant).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Acute Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
    <description>Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relief Pro cream</intervention_name>
    <description>Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.</description>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relief Pro rectal suppositories</intervention_name>
    <description>Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice</description>
    <arm_group_label>Patients with acute hemorrhoids</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male and female patients with acute hemorrhoids from Russia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &amp; female patients 18 to 65 years old;

          -  Patients with acute hemorrhoids 1 and 2 stage (with thrombosis (external, internal,
             mixed), including cases with bleeding);

          -  Prescription of fluocortolone + lidocaine as a part of routine clinical practice.

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice;

          -  Hemorrhoid with stage Ëƒ II;

          -  Contraindications for use of Relief PRO in the approved product label;

          -  Anemia and/or severe/profuse hemorrhoid bleeding;

          -  Surgery in perianal region in anamnesis;

          -  Concomitant treatment with antibiotics/antiseptics, antithrombotics, antineoplastic
             and/or immunosuppressant;

          -  Inflammatory bowel disease;

          -  Hepatic diseases in severe and acute stages;

          -  Colorectal cancer;

          -  Purulent-inflammatory diseases of the perianal region and anal canal;

          -  Chronic pulmonary diseases in severe and acute stages.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State Scientific Center of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

